Table 9.1
Drug-specific and patient factors to consider when selecting antihyperglycemic treatment in adults with type 2 diabetes
 |
| |
*For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing information.
†FDA approved for CVD benefit. CHF, congestive heart failure; CV, cardiovascular; DPP-4, dipeptidyl peptidase 4; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; GLP-1 RAs, glucagon-like peptide 1 receptor agonists; NASH, nonalcoholic steatohepatitis; SGLT2, sodium–glucose cotransporter 2; SQ, subcutaneous; T2DM, type 2 diabetes.